Clinical Value of Detecting MYD88 L265P Mutation in the Plasma of Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma via Droplet Digital PCR
Blood tests detecting a specific cancer mutation help identify high-risk lymphoma patients and track response to treatment non-invasively.
In 158 treatment-naive DLBCL patients, ddPCR detection of MYD88 L265P in plasma cfDNA identifies a poor-prognosis subgroup with shorter progression-free survival and higher disease burden markers. Serial monitoring of cfDNA variant allele frequency provides a non-invasive tool for treatment response assessment and prognostic stratification in DLBCL.
What the study was
- Study design
- Retrospective cohort study
- Population
- Treatment-naive DLBCL patients, Shanxi, China
- Sample size
- 158
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Zhongguo Shi Yan Xue Ye Xue Za Zhi
Why it surfaced
Validates ddPCR-based plasma MYD88 L265P monitoring in DLBCL in a reasonably-sized Chinese cohort (n=158); adds prognostic dimension to cfDNA monitoring for DLBCL. Retrospective design limits evidence strength.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.